GSD/GLA registry Freiburg - Register for Gorham-Stout-Disease (GSD) and generalised lymphatic anomalies (GLA) -

Organizational Data

DRKS-ID:
DRKS00007182
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2015-06-17
Last update in DRKS:
2023-07-28
Registration type:
Retrospective

Acronym/abbreviation of the study

GSD/GLA-Registry

URL of the study

No Entry

Brief summary in lay language

The GLA is a very rare disease which is marked by an increase of lymphatic vessels. Besides, bones, internal organs, soft part fabrics and the skin can be concerned. This disease appears predominantly with children and young adults. Treatments can be carried out according to propagation of the lymphatic vessels by drugs and if necessary also by radiotherapy. At the moment there is still no academically secure knowledge about the origin of the diesease and the suitable risk factors which favour the origin of the GLA. The GSD is an extremely rare disease with which bones are dissolved and are replaced with lymphatic tissue. The messenger's material Interleukin-6 seems to be involved in these disease events decisively. Bone-diminishing cells and the appearance of distensions in the area of the blood vessels and lymphatic vessels seem to be significant with these illness events. At the moment there is still no generally approved therapy procedure. Beside surgical interventions, radiotherapy and chemotherapy as well as Bisphosphonate and interferon alpha 2 are applied. GSD as well as GLA are seldom appearing diseases with partly serious complications. The aim of the register is the systematic and central registration of the illness course of the affected patients. By the collection of this information and scientific evaluation we get more knowledge about these diseases. The strategies of treatment can be thereby improved in the longer term for the affected patients, according to the actual knowledge.

Brief summary in scientific language

The Gorham-Stout-Disease (GSD) and the generalised lymphatic anomalies (GLA) are rare diseases. Both appear predominantly with children and young adults and one can separate them hardly of each other. The GLA is marked by a vague increase of lymphatic vessels, among the rest, bones, internal organs, soft tissue and skin can be concerned. It also often comes to hemorrhages. With the GSD it comes above all for dissolving of osseous substance and the skeletal segments are replaced by lymphatic vessels. It also comes to the infestation of soft tissue, as well as internal organs like the spleen, the liver and the lung. Thus it can come to serious complications like osseous breaks or lung failure. Nevertheless, the illness course as well as the development of the diseases varies a lot individually. Different attempts of treatment with drugs, radio therapy and also surgical interventions are undertaken. There is not a standardised procedure of treatment, nevertheless, up to now. Also the causes of the diseases are still widely unknown. With the GSD the messenger's material Interleukin-6 seems to be involved in the illness events decisively. The aim of the register is the systematic registration of patients with GSD/GLA with the help of a registration curve. By the accumulated information and scientific evaluation it is possible to get to know the illnesses better and to optimise in the longer term the strategies of treatment according to the actual level of knowledge. Besides the care of the affected patients and the consultation of the treating doctors can be improved thus. It may also answer scientific questions, as for example the aetiology of the diseases.

Health condition or problem studied

ICD10:
M89.5 - Osteolysis
ICD10:
I89 - Other noninfective disorders of lymphatic vessels and lymph nodes
ICD10:
D18.1 - Lymphangioma, any site
Free text:
Gorham-Stout-Disease (GSD)
Free text:
Generalized Lymphatic Anomalies (GLA)
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
The aim of the register is the systematic and central registration of the illness course of patients with Gorham-Stout-Disease and generalised lymphatic anomalies. By the collection of this information and the scientific evaluationwe win more knowledge about these diseases. The strategies of treatment can be thereby improved in the longer term for the affected patients, according to the actual knowledge.

Endpoints

Primary outcome:
The aim of the registry is the systematic and central registration of the illness course of the patients with Gorham-Stout-Disease (GSD) and generalised lymphatic anomalies (GLA) with the help of a registration curve.
Secondary outcome:
By the accumulated information and scientific evaluation it is possible to get to know the diseases better and to optimise in the longer term the strategies of treatment according to the actual level of knowledge. Besides the care of the affected patients and the consultation of the treating doctors can be improved thus. It may also answer scientific questions, as for example the aetiology of the diseases.

Study Design

Purpose:
Prognosis
Retrospective/prospective:
No Entry
Study type:
Non-interventional
Longitudinal/cross-sectional:
No Entry
Study type non-interventional:
Epidemiological study

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Austria
  • Germany
  • Switzerland
Number of study centers:
Multicenter study
Recruitment location(s):
  • Medical center Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin Freiburg

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2014-09-18
Planned study completion date:
No Entry
Actual Study Completion Date:
2022-12-23
Target Sample Size:
50
Final Sample Size:
31

Inclusion Criteria

Sex:
All
Minimum Age:
no minimum age
Maximum Age:
no maximum age
Additional Inclusion Criteria:
All patients with Gorham-Stout-Disease/the generalised lymphatic anomalies which have given their written consent are enclosed.

Exclusion Criteria

The patients with missing, or secluded consent are excluded to the participation in the register.

Addresses

Primary Sponsor

Address:
Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin, Klinik IV, Pädiatrische Hämatologie/Onkologie
Mathildenstr. 1
79106 Freiburg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Universitätsklinikum Freiburg, ZKJ, Pädiatrische Hämatologie/Onkologie,
Prof. Dr. med Jochen Rössler
Mathildenstr. 1
79106 Freiburg
Germany
Telephone:
0761-270-43000
Fax:
0761-270-46990
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin
Dr. med. Friedrich Kapp
Mathildenstraße 1
79106 Freiburg
Germany
Telephone:
+49 761 270 46211
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Universitätsklinikum Freiburg, ZKJ, Pädiatrische Hämatologie/Onkologie,
Prof. Dr. med Jochen Rössler
Mathildenstr. 1
79106 Freiburg
Germany
Telephone:
0761-270-43000
Fax:
0761-270-46990
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin, Klinik IV, Pädiatrische Hämatologie/Onkologie
Mathildenstr. 1
79106 Freiburg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
Engelberger Str. 21
79106 Freiburg
Germany
Telephone:
+49-761-27072600
Fax:
+49-761-27072630
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2014-06-18
Ethics committee number:
310/14
Vote of the Ethics Committee:
Approved
Date of the vote:
2014-09-18

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
only by publication

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry